Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Beconase switch review

This article was originally published in The Tan Sheet

Executive Summary

Beconase switch review: FDA Nonprescription Drugs and Pulmonary-Allergy Drugs Advisory Committees scheduled Sept. 19 consideration of the proposed Rx-to-OTC switch of the beclomethasome dipropionate nasal spray .042% is postponed, according to Glaxo. In order to address some issues raised in its discussions with FDA, Glaxo has requested that the meeting be postponed for an undetermined period of time. Glaxo had been planning to present studies in support of the switch at the meeting ("The Tan Sheet" Aug. 4, p. 1). NDA 20-840, filed by Glaxo Wellcome in December, is for OTC treatment and prevention of seasonal allergic rhinitis symptoms in people over the age of 12. If approved, the OTC nasal spray will be marketed by Warner-Lambert under the firms' joint venture. Schering-Plough also has an NDA pending for a product -- Vancenase -- with the same active ingredient at the same dosage, but had postponed its committee review in September 1996 to allow time for additional data to be analyzed and presented to the committees ("The Tan Sheet" Sept. 30, 1996, p. 9)...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel